"At OHC, our search for new treatments is relentless. Our drive to provide superior care runs deep. And our fight against cancer is personal. Our independent, physician-led practice is known for delivering clinical excellence combined with unmatched personal and emotional support in neighborhoods throughout the region. At OHC: • Renowned experts aggressively attack your cancer with every possible strategy. • Our nationally recognized clinical trials team is located here in the region and engaged in a passionate search for innovative treatments. • Navigators help you manage finances, understand your disease and gain power over cancer's impact on your personal life. OHC has been fighting cancer on the front lines for more than 35 years. We ar"

During the past decade, Oncology Hematology Care Inc-Healthplex conducted 44 clinical trials. In the 10-year time frame, 44 clinical trials started and 55 clinical trials were completed, i.e. on average, 125% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 44 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Oncology Hematology Care Inc-Healthplex" #1 sponsor was "National Cancer Institute (NCI)" with 36 trials, followed by "SWOG Cancer Research Network" with 20 trials sponsored, "Alliance for Clinical Trials in Oncology" with 11 trials sponsored, "ECOG-ACRIN Cancer Research Group" with 7 trials sponsored and "Gynecologic Oncology Group" with 7 trials sponsored. Other sponsors include 3 different institutions and companies that sponsored additional 10 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Oncology Hematology Care Inc-Healthplex" #1 collaborator was "National Cancer Institute (NCI)" with 45 trials as a collaborator, "Canadian Cancer Trials Group" with 6 trials as a collaborator, "NRG Oncology" with 6 trials as a collaborator, "Astellas Pharma Inc" with 2 trials as a collaborator and "Astellas Pharma US, Inc." with 1 trials as a collaborator. Other collaborators include 9 different institutions and companies that were collaborators in the rest 19 trials.

According to Clinical.Site data, the most researched conditions in "Oncology Hematology Care Inc-Healthplex" are "Recurrent Squamous Cell Lung Carcinoma" (9 trials), "Stage IV Squamous Cell Lung Carcinoma AJCC v7" (7 trials), "Breast Cancer" (5 trials), "Recurrent Breast Carcinoma" (5 trials) and "Recurrent Ovarian Carcinoma" (4 trials). Many other conditions were trialed in "Oncology Hematology Care Inc-Healthplex" in a lesser frequency.

Most popular intervention types in "Oncology Hematology Care Inc-Healthplex" are "Drug" (77 trials), "Other" (60 trials), "Biological" (27 trials), "Procedure" (15 trials) and "Radiation" (7 trials). Other intervention types were less common.

The name of intervention was led by "Laboratory Biomarker Analysis" (42 trials), "Quality-of-Life Assessment" (19 trials), "Carboplatin" (12 trials), "Cisplatin" (10 trials) and "Docetaxel" (9 trials). Other intervention names were less common.

The vast majority of trials in "Oncology Hematology Care Inc-Healthplex" are 67 trials for "All" genders and 18 trials for "Female" genders.

Currently, there are NaN active trials in "Oncology Hematology Care Inc-Healthplex". undefined are not yet recruiting, 8 are recruiting, 50 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 22 completed trials in Oncology Hematology Care Inc-Healthplex, undefined suspended trials, and 5 terminated clinical trials to date.

Out of the total trials that were conducted in Oncology Hematology Care Inc-Healthplex, 4 "Phase 1" clinical trials were conducted, 43 "Phase 2" clinical trials and 46 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".